Our pipeline “IMPACT” (IMProving Personalized Adoptive Cell Therapy) allows us to identify tumor-reactive T cells and isolate unique T cell receptors (TCR)  from each patient’s tumor. 
Using IMPACT we generate the product “UNIPACT” (UNIversal Personalized Adoptive Cell Therapy) using patient-specific TCR-transgenic T cells via our nanoSMAR vector.



Cancer vaccines 

Tcelltech has also developed peptide vaccines targeting the two most common mutations in incurable brain tumors (IDH1R132H and H3K27M).

Our IDH1R132H SCA-VAC has completed Phase I trial (32 patients, 21 grade 3, 11 grade 4), meeting both primary endpoints.

We currently prepare IDH1 for out-licensing to industrial partners.


© 2022 Tcelltech GmbH. All rights reserved.

Responsible Provider in accordance with § 5 of the German Telemedia Act (TMG):

Tcelltech GmbH

Cubex One

Franz-Volhard-Straße 5

68168 Mannheim


T + 49 178 730 730 2





Michael Platten, Richard Harbottle, Edward Green, Mathias Turwitt

Commercial register/register number

District Court of Mannheim HRB 745 600

VAT number 

not yet available